GWP42003-P + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Rett Syndrome
Conditions
Rett Syndrome, RTT
Trial Timeline
Jul 29, 2019 → Jan 21, 2021
NCT ID
NCT03848832About GWP42003-P + Placebo
GWP42003-P + Placebo is a phase 3 stage product being developed by Jazz Pharmaceuticals for Rett Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT03848832. Target conditions include Rett Syndrome, RTT.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05288283 | Phase 3 | Terminated |
| NCT04745026 | Phase 2 | Completed |
| NCT04421456 | Phase 2 | Terminated |
| NCT03848832 | Phase 3 | Terminated |
| NCT02607891 | Phase 2 | Completed |
| NCT02544763 | Phase 3 | Completed |
Competing Products
20 competing products in Rett Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Esomeprazole + Aspirin + Rofecoxib | AstraZeneca | Approved | 85 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Esomeprazole Magnesium | AstraZeneca | Approved | 85 |
| AZD5213 and placebo | AstraZeneca | Phase 2 | 52 |
| fingolimod (FTY720) | Novartis | Phase 1/2 | 41 |
| PF-03654746 + Placebo + Placebo + PF-03654746 | Pfizer | Phase 2 | 51 |
| Aripiprazole | Bristol Myers Squibb | Pre-clinical | 22 |
| NBI-98854 | Neurocrine Biosciences | Phase 2 | 49 |
| Valbenazine + Placebo oral capsule | Neurocrine Biosciences | Phase 2 | 49 |
| Valbenazine | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 | Neurocrine Biosciences | Phase 1 | 30 |
| Valbenazine + Placebo oral capsule | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| Valbenazine | Neurocrine Biosciences | Phase 2 | 49 |
| NBI-98854 + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| Abobotulinum toxin A | Ipsen | Pre-clinical | 20 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| trofinetide | Acadia Pharmaceuticals | Phase 3 | 72 |
| Trofinetide | Acadia Pharmaceuticals | Phase 3 | 72 |
| Trofinetide | Acadia Pharmaceuticals | Phase 2/3 | 60 |